EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hyloris Pharmaceuticals EBITDA Margin % Related Terms
Hyloris Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0AB6 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Hyloris Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyloris Pharmaceuticals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hyloris Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyloris Pharmaceuticals (LTS:0AB6) has a EBITDA Margin % of -61.85% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hyloris Pharmaceuticals and its competitors. According to the industry distribution chart, Hyloris Pharmaceuticals ranks #486 out of 944 companies in the Biotechnology industry, placing it in the top 51.5%.
Is Hyloris Pharmaceuticals' EBITDA Margin % too high?
Hyloris Pharmaceuticals' current EBITDA Margin % is -61.85%. Based on the distribution chart, Hyloris Pharmaceuticals ranks #486 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Hyloris Pharmaceuticals has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hyloris Pharmaceuticals ranks #486 out of 944 companies for EBITDA Margin %. This places Hyloris Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hyloris Pharmaceuticals and its competitors. Hyloris Pharmaceuticals's current EBITDA Margin % is -61.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (LTS:0AB6) is currently considered Possible Value Trap. The stock's GF Value™ is €9.49, compared to a current price of €4.52 — trading 52.4% below its estimated fair value. The current EBITDA Margin % is -61.85%. Hyloris Pharmaceuticals' overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current EBITDA Margin % is -61.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.52 is trading 52.4% below its estimated GF Value™ of €9.49.
GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.
Key valuation signals for LTS:0AB6:
EBITDA Margin %: -61.85%
GF Value™: €9.49 vs. price of €4.52 (52.4% below fair value)
No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
63GF Score
Get the complete analysis for LTS:0AB6
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0AB6 has been successfully added to your 
